Join us Oct. 17 for a Fireside Chat with Jim Greenwood, senior policy advisor, DLA Piper, former U.S. Congressman & CEO of BIO plus Ron Philip, CEO, Spark Therapeutics & John Crowley, CEO, Amicus Therapeutics! <<Register here>>

About Us

The Baruch S. Blumberg Institute is an independent nonprofit research institute, established in 2003 by the Hepatitis B Foundation to advance its research mission. Today, it is one of the nation’s leading centers for translational research, particularly for hepatitis B and liver cancer.  The Blumberg Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease, and liver cancer in an environment conducive to interaction, collaboration and focus.

To view our 2022 Annual Report which details our research, outreach, public health and advocacy accomplishments for each year click here.

 To learn more about the Blumberg Institute, please watch this brief overview video:

 

Our Mission

The mission of the Baruch S. Blumberg Institute is to use discovery science to find new therapies and biomarkers for hepatitis B and liver cancer; to advance its research discoveries through traditional scholarship and educational opportunities; to nurture biotechnology; and to promote public health outreach programs to improve the quality of life for those affected by chronic hepatitis B worldwide.

Support Us

The Baruch S. Blumberg Institute is a global leader in research on hepatitis B and liver cancer. Be a part of our story and help fuel the work toward a cure!

Show your support today!

 

 

Donate